drugset / Trial / NCT00110305
A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the dose-response relationship of antiviral activity after 48 weeks treatment with 3 different dose regimens of TMC278.
Timeline
- Start
- 2005-06
- Primary completion
- 2011-12
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Efavirenz | Other / unclassified | 600 mg | — |
| Subject | Rilpivirine | Small molecule | 25 mg | — |
| Subject | Rilpivirine | Small molecule | 75 mg | — |
| Subject | Rilpivirine | Small molecule | 150 mg | — |
| Background | Lamivudine | Other / unclassified | — | — |
| Background | Tenofovir disoproxil fumarate | Small molecule | — | — |
| Background | Zidovudine | Small molecule | — | — |
| Background | emtricitabine | Other / unclassified | — | — |